PET
0.019
171.4%
STP
0.265
-44.2%
CKA
0.073
69.8%
VBS
0.11
-37.1%
A1G
0.52
65.1%
IPB
0.006
-33.3%
APC
0.015
50%
NAE
0.002
-33.3%
AYT
0.006
50%
SFG
0.002
-33.3%
ERA
0.003
50%
OVT
0.005
-28.6%
RMY
0.045
45.2%
VUL
4.41
-27.5%
TCG
0.75
38.9%
IMI
0.011
-26.7%
QFE
0.081
37.3%
CTN
0.003
-25%
PNN
0.12
36.4%
MAY
0.009
-25%
DAL
0.054
35%
RKB
0.003
-25%
DMG
0.008
33.3%
NFM
0.016
-23.8%
FBR
0.004
33.3%
EPI
1.005
-23.3%
MRQ
0.004
33.3%
IBX
0.02
-23.1%
BDG
0.08
29%
RML
0.053
-22.1%
MGA
0.081
28.6%
AUR
0.018
-21.7%
NES
0.009
28.6%
LMG
0.023
-20.7%
GR8
0.205
28.1%
AKN
0.004
-20%
EDU
0.77
27.3%
FCT
0.008
-20%
PKY
0.019
26.7%
GLL
0.008
-20%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PharmAust Limited (ASX:PAA): Developing new treatments for neurodegenerative diseases

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, PharmAust’s (ASX:PAA) Managing Director Dr Michael Thurn speaks with The Stock Network’s Lel Smits about:

🧬 A re-prioritised commercialisation strategy: PharmAust focus on neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s disease
🧬 Monepantel gets US FDA Orphan Drug Designation for treatment of ALS:
Next steps following PharmAust’s Monepantel recently granted Orphan Drug Designation for the treatment of ALS by the US FDA

Watch the full interview ⚡️ https://youtu.be/VJkvSG3bkrA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697